

### What is already known on this topic

Evidence from randomised controlled trials of angiotensin receptor blockers has shown variable effects on cardiovascular events

A recent editorial implied that angiotensin receptor blockers increase the risk of myocardial infarction

### What this study adds

Our systematic review of all available data on angiotensin receptor blockers shows a neutral (not increased) impact of these agents on myocardial infarction

Although ACE inhibitors remain the agents of choice to reduce myocardial infarction, patients and healthcare providers need not worry about angiotensin receptor blockers increasing patients' risk for myocardial infarction

and has received honorariums and research grants from Merck Frosst, Merck-Schering, Pfizer, Sanofi-Aventis, and Novartis.  
Ethical approval: Not required.

- Levy BI. Can angiotensin II type II receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. *Circulation* 2004;109:8-13.
- Swedberg K, McMurray JJV. Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT? *Eur Heart J* 2004;25:357-8.
- McMurray JJV. Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. *Heart* 2001;86:97-103.
- Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 2003;349:1893-906.
- Dickstein K, Kjekshus J, the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. *Lancet* 2002;360:752-60.
- Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the losartan heart failure survival study ELITE II. *Lancet* 2000;355:1582-7.
- Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. *BMJ* 2004;329:1248-9.
- Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. *J Hypertens* 2003;21:875-86.
- Bakris G, Sica D, Ram V, Fagan T, Vaitkus PT, Anders RJ. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. *Am J Hypertens* 2002;15:53-7.
- Haneda M, Kikkawa R, Sakai H, Kawamori R. Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. *Diabetes Res Clin Pract* 2004;66:87-95.
- Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001;345:861-9.
- Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. *Ann Intern Med* 2003;138:542-9.
- Matsumori A, on behalf of the assessment of response to candesartan in heart failure in Japan (ARCH-J) study investigators. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. *Eur J Heart Fail* 2003;5:669-77.
- McMurray JJV, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. *Lancet* 2003;362:767-71.
- Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. *Lancet* 2003;362:772-6.
- Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. *Lancet* 2003;362:777-81.
- Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. *Am Heart J* 2000;139:609-17.

- Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med* 2001;345:1667-75.
- Targum SL, Hung HMJ. Medical-statistical review: NDA 20-665/SE1-016 and 21-283/SE-001 Diovan (valsartan) capsules and tablets. 2001. [www.fda.gov/cder/foi/nda/2002/21-283S001\\_Diovan\\_medr\\_P3.pdf](http://www.fda.gov/cder/foi/nda/2002/21-283S001_Diovan_medr_P3.pdf) (accessed 2 Apr 2005).
- Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. *N Engl J Med* 2004;351:1952-61.
- Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). *Lancet* 1997;349:747-52.
- Willenheimer R, Helmers C, Pantev E, Rydberg E, Lofdahl P, Gordon A, for the Heart Failure Valsartan Exercise Capacity Evaluation (HEAVEN) Study Group. Safety and efficacy of valsartan versus enalapril in heart failure patients. *Int J Cardiol* 2002;85:261-70.
- Dunselman PHJM. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. *Int J Cardiol* 2001;77:131-8.
- Di Pasquale P, Bucca V, Scalzo S, Cannizzaro S, Giubilato A, Paterna S. Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study. *Heart* 1999;81:606-11.
- Spinar J, Vitovec J, Spinarova L, Pluhacek L, Fischerova B, Toman J. A comparison of intervention with losartan or captopril in acute myocardial infarction. *Eur J Heart Fail* 2000;2:91-100.
- McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, and their combination in congestive heart failure. The randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. *Circulation* 1999;100:1056-64.
- Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. *Ann Intern Med* 2004;141:693-704.
- ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ace intolerant subjects with cardiovascular disease (ONTARGET/TRANSCEND) trials. *Am Heart J* 2004;148:52-61.

(Accepted 1 August 2005)

doi 10.1136/bmj.38595.518542.3A

### Corrections and clarifications

*Screening for abdominal aortic aneurysms: single centre randomised controlled trial*

A couple of errors crept into this paper by Jes S Lindholt and colleagues (*BMJ* 2005;330:750-2). Firstly, the number of participants in the intervention group who were screened was 4852 (not 4860, as stated in the abstract and the results section). Secondly, the Y axis in figure 2 (figure 3 in the full version of the article on bmj.com) should be 0, 50, 100, 150, and 200 (not 0, 1, 2, 3, and 4).

*Midlife obesity increases risk of future dementia*

The final letter of the first author's name somehow "dropped off" during the editing of this letter by George Razay and Anthea Vreugdenhil (*BMJ* 2005;331:455, 20-27 Aug). The error has been corrected on bmj.com.

*Comparison of amount of biomedical research originating from the European Union and the United States*

The authors of this paper, Elpidoforos S Soteriades and Matthew E Falagas, have alerted us to errors in two columns of their table (*BMJ* 2005;331:192-4, 23 Jul). For the columns headed "Papers per \$bn" and "Citations per \$bn" the authors should have supplied values a 10th lower; therefore the given values should all have a decimal point before the final digit (although for Malta the given value 0.2 is correct). In addition, during editing we mangled the average population of France: it should be 58.6 (not 5.6) million.